Acadia Pharma Q4 net income $45.8M; 2023 revenue $726.4M (+40%); FY2024 DAYBUE guide $370-420M

ACADIA PHARMACEUTICALS INC

2023-FY EPS reported -$0.37 revenue$726,437,000

Q4 2023 net income $45.8M ($0.28 EPS) vs net loss $41.7M ($0.26 loss) in Q4 2022.
Full year 2023 net loss $61.3M ($0.37 loss) vs net loss $216.0M ($1.34 loss) in 2022.
2023 total net product sales $726.4M (+40% YoY); DAYBUE $177.2M, NUPLAZID $549.2M (+6%).
FY2024 guidance: DAYBUE net sales $370-420M; NUPLAZID $560-590M; R&D $305-325M; SG&A $455-480M.
Phase 3 ADVANCE-2 (pimavanserin for negative schizophrenia) top-line results due by end of Q1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

ACADIA PHARMACEUTICALS INC updated its Full Year 2024 guidance (initiated).

Period: Full Year 2024
Guidance: initiated
Result: guidance update

Exact text from the filing

Full Year 2024 Financial Guidance • DAYBUE net product sales in the range of $370 to $420 million. • NUPLAZID net product sales in the range of $560 to $590 million. • GAAP R&D expense in the range of $305 to $325 million. • GAAP SG&A expense in the range of $455 to $480 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

ACADIA PHARMACEUTICALS INC reported fourth quarter and full year ended December 31, 2023 results: revenue $231.0 million for the fourth quarter of 2023 and $726.4 million for the full year 2023, net income net income of $45.8 million for the fourth quarter of 2023 and net loss of $61.3 million for the full year 2023, EPS $0.28 per common share for the fourth quarter and $(0.37) per common share for the full year.

Period: fourth quarter and full year ended December 31, 2023
Revenue: $231.0 million for the fourth quarter of 2023 and $726.4 million for the full year 2023
Net income: net income of $45.8 million for the fourth quarter of 2023 and net loss of $61.3 million for the full year 2023
EPS: $0.28 per common share for the fourth quarter and $(0.37) per common share for the full year
Result: reported results

Exact text from the filing

Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

ACADIA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0000950170-24-021169

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.